COVID-19 vaccines: where we stand and challenges ahead.
COVID-19 vaccines: where we stand and challenges ahead.
复制标题
DOI：
10.1038/s41418-020-00720-9
复制
发表时间：
2021-03
影响因子：
12.4
通讯作者：
COVID-19 Commission of Accademia Nazionale dei Lincei, Rome
中科院分区：
文献类型：
--
作者：
Forni G;Mantovani A;COVID-19 Commission of Accademia Nazionale dei Lincei, Rome
自识别 SARS-CoV-2 病毒及其基因组以来的 11 个月里，科学界的非凡努力已导致 300 多个疫苗项目的开发。超过40个目前正在进行临床评估，其中10个正在进行III期临床试验，其中3个已结束III期临床试验并取得积极结果。其中一些新疫苗正在被批准用于紧急使用。现有数据表明，新的候选疫苗可能有助于保护个人和减少大流行的传播。所利用的概念和技术平台是多种多样的，并且不同的疫苗可能会更适合不同的人群。此外，尚待阐明的是，正在评估的疫苗以及卡介苗等不相关疫苗的能力是否以及在多大程度上可以通过训练针对 SARS-CoV-2 的先天免疫和病原体不可知的保护来提高免疫适应性。由于开发时间短且所采用的技术新颖，这些疫苗的部署将存在一些尚未解决的问题，只有随着时间的推移才能澄清。与生产数十亿剂疫苗相关的技术问题以及与在最贫穷国家提供这些疫苗相关的道德问题是我们面临的迫在眉睫的挑战。我们的宗旨是，从长远来看，将需要不止一种疫苗来确保全球公平获取、保护不同受试者以及对病毒变种的免疫力。
In the eleven months elapsed since the identification of the SARS-CoV-2 virus and its genome, an exceptional effort by the scientific community has led to the development of over 300 vaccine projects. Over 40 are now undergoing clinical evaluation, ten of these are in Phase III clinical trials, three of them have ended Phase III with positive results. A few of these new vaccines are being approved for emergency use. Existing data suggest that new vaccine candidates may be instrumental in protecting individuals and reducing the spread of pandemic. The conceptual and technological platforms exploited are diverse, and it is likely that different vaccines will show to be better suited to distinct groups of the human population. Moreover, it remains to be elucidated whether and to what extent the capacity of vaccines under evaluation and of unrelated vaccines such as BCG can increase immunological fitness by training innate immunity to SARS-CoV-2 and pathogen-agnostic protection. Due to the short development time and the novelty of the technologies adopted, these vaccines will be deployed with several unresolved issues that only the passage of time will permit to clarify. Technical problems connected with the production of billions of doses and ethical ones connected with the availably of these vaccines also in the poorest countries, are imminent challenges facing us. It is our tenet that in the long run more than one vaccine will be needed to ensure equitable global access, protection of diverse subjects and immunity against viral variants.
登录
查看更多内容
影响因子：
3.7
作者：
Bottazzi B;Santini L;Savino S;Giuliani MM;Dueñas Díez AI;Mancuso G;Beninati C;Sironi M;Valentino S;Deban L;Garlanda C;Teti G;Pizza M;Rappuoli R;Mantovani A
通讯作者：
Mantovani A
DOI：
10.15585/mmwr.mm6938e1
发表时间：
2020-09-25
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Delahoy MJ;Whitaker M;O'Halloran A;Chai SJ;Kirley PD;Alden N;Kawasaki B;Meek J;Yousey-Hindes K;Anderson EJ;Openo KP;Monroe ML;Ryan PA;Fox K;Kim S;Lynfield R;Siebman S;Davis SS;Sosin DM;Barney G;Muse A;Bennett NM;Felsen CB;Billing LM;Shiltz J;Sutton M;West N;Schaffner W;Talbot HK;George A;Spencer M;Ellington S;Galang RR;Gilboa SM;Tong VT;Piasecki A;Brammer L;Fry AM;Hall AJ;Wortham JM;Kim L;Garg S;COVID-NET Surveillance Team
通讯作者：
COVID-NET Surveillance Team
影响因子：
30.5
作者：
Brunetta, Enrico;Folci, Marco;Mantovani, Alberto
通讯作者：
Mantovani, Alberto
影响因子：
64.5
作者：
Hoffmann, Markus;Kleine-Weber, Hannah;Poehlmann, Stefan
通讯作者：
Poehlmann, Stefan
DOI：
10.1056/nejmoa2028436
发表时间：
2020-12-17
期刊：
The New England journal of medicine
影响因子：
--
作者：
Anderson EJ;Rouphael NG;Widge AT;Jackson LA;Roberts PC;Makhene M;Chappell JD;Denison MR;Stevens LJ;Pruijssers AJ;McDermott AB;Flach B;Lin BC;Doria-Rose NA;O'Dell S;Schmidt SD;Corbett KS;Swanson PA 2nd;Padilla M;Neuzil KM;Bennett H;Leav B;Makowski M;Albert J;Cross K;Edara VV;Floyd K;Suthar MS;Martinez DR;Baric R;Buchanan W;Luke CJ;Phadke VK;Rostad CA;Ledgerwood JE;Graham BS;Beigel JH;mRNA-1273 Study Group
通讯作者：
mRNA-1273 Study Group